Active, not recruitingPHASE2, PHASE3NCT06073132
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Studying Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- TWi Biotechnology, Inc.
- Intervention
- AC-203(drug)
- Enrollment
- 80 enrolled
- Eligibility
- All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- Mission dermatology Center, Rancho Santa Margarita, California, United States
- Stanford University, Stanford, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Pediatric Skin Research, LLC, Miami, Florida, United States
- Northwestern University - Lurie Childrens's Hospital, Chicago, Illinois, United States
- Stony Brook Dermatology, Stony Brook, New York, United States
- Cincinnati Childrens Hospital, Cincinnati, Ohio, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
- Royal Melbourne Hospital, Melbourne, Victoria, Australia
- Premier Specialists, Kogarah, Australia
- Sydney Children's Hospital, Randwick, Australia
- Universitaetsklinik fuer Dermatologie und Allergologie, Salzburg, Austria
- UZ Leuven, Leuven, Belgium
- Hopital Necker-Enfants Malades, Paris, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06073132 on ClinicalTrials.govOther trials for Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form
Additional recruiting or active studies for the same condition.
See all trials for Autosomal dominant generalized epidermolysis bullosa simplex, intermediate form →